N
Nathanael S. Gray
Researcher at Stanford University
Publications - 776
Citations - 72416
Nathanael S. Gray is an academic researcher from Stanford University. The author has contributed to research in topics: Kinase & Cyclin-dependent kinase. The author has an hindex of 119, co-authored 720 publications receiving 59748 citations. Previous affiliations of Nathanael S. Gray include University of California, Berkeley & Dana Corporation.
Papers
More filters
Journal ArticleDOI
Targeting cancer with small molecule kinase inhibitors
TL;DR: This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors, and discusses the current challenges in the field.
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Aravind Subramanian,Rajiv Narayan,Steven M. Corsello,Steven M. Corsello,David Peck,Ted Natoli,Xiaodong Lu,Joshua Gould,John F. Davis,Andrew A. Tubelli,Jacob K. Asiedu,David L. Lahr,Jodi E. Hirschman,Zihan Liu,Melanie Donahue,Bina Julian,Mariya Khan,David Wadden,Ian Smith,Daniel D. Lam,Arthur Liberzon,Courtney Toder,Mukta Bagul,Marek Orzechowski,Oana M. Enache,Federica Piccioni,Sarah A. Johnson,Nicholas J. Lyons,Alice H. Berger,Alice H. Berger,Alykhan F. Shamji,Angela N. Brooks,Angela N. Brooks,Anita Vrcic,Corey Flynn,Jacqueline Rosains,David Y. Takeda,David Y. Takeda,Roger Hu,Desiree Davison,Justin Lamb,Kristin Ardlie,Larson Hogstrom,Peyton Greenside,Nathanael S. Gray,Nathanael S. Gray,Paul A. Clemons,Serena J. Silver,Xiaoyun Wu,Wen-Ning Zhao,Wen-Ning Zhao,Willis Read-Button,Xiaohua Wu,Stephen J. Haggarty,Stephen J. Haggarty,Lucienne Ronco,Jesse S. Boehm,Stuart L. Schreiber,Stuart L. Schreiber,Stuart L. Schreiber,John G. Doench,Joshua A. Bittker,David E. Root,Bang Wong,Todd R. Golub +64 more
TL;DR: The expanded CMap is reported, made possible by a new, low-cost, high-throughput reduced representation expression profiling method that is shown to be highly reproducible, comparable to RNA sequencing, and suitable for computational inference of the expression levels of 81% of non-measured transcripts.
Journal ArticleDOI
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Carson C. Thoreen,Seong A. Kang,Jae Won Chang,Qingsong Liu,Jianming Zhang,Yi Gao,Laurie J. Reichling,Taebo Sim,David M. Sabatini,Nathanael S. Gray +9 more
TL;DR: It is found that Torin1, a highly potent and selective ATP-competitive mTOR inhibitor that directly inhibits both complexes, impairs cell growth and proliferation to a far greater degree than rapamycin.
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.